Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 6:44 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 21 - 40 ( 110 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bayer Terminates Licensing Agreement; 1Q22 Financials; Modulating PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Eyes Focused On Interim Analysis of MS Drug in July
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hosted R&D Event on Treating Multiple Sclerosis
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Business Update, MS Drug Update in March; Interim Analysis in Q2
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment in ATA2271''s Phase 1 Trial Paused; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Manufacturing Partnership Inked With FUJIFILM Subsidiary; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sells Manufacturing Facility to Extend Cash Runway
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nature and Science Support ATRA Therapy to Treat Multiple Sclerosis
Provider: Roth Capital Partners, Inc.
Analyst: Research Department